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http://dx.doi.org/10.1016/j.ccell.2015.03.009SUMMARYSpecific combinations of acute myeloid leukemia (AML) disease alleles, including FLT3 and TET2mutations,
confer distinct biologic features and adverse outcome. We generated mice with mutations in Tet2 and Flt3,
which resulted in fully penetrant, lethal AML. Multipotent Tet2/;Flt3ITD progenitors (LSK CD48+CD150)
propagate disease in secondary recipients and were refractory to standard AML chemotherapy and FLT3-
targeted therapy. Flt3ITD mutations and Tet2 loss cooperatively remodeled DNA methylation and gene
expression to an extent not seen with either mutant allele alone, including at the Gata2 locus. Re-expression
ofGata2 induced differentiation in AML stem cells and attenuated leukemogenesis. TET2 and FLT3mutations
cooperatively induce AML, with a defined leukemia stem cell population characterized by site-specific
changes in DNA methylation and gene expression.INTRODUCTION
Acute myeloid leukemia (AML) is the most common acute
leukemia in adults; unfortunately, most patients relapse andSignificance
Specific combinations of AML disease alleles confer adverse
not exist for the majority of common, poor-prognosis genotyp
to induce AML using amousemodel. Thismodel has a defined
tional and epigenetic profile and is critical for therapeutic targ
ease alleles to target multiple loci. These data also suggest th
reversible and therapies that reactivate silenced genes may im
502 Cancer Cell 27, 502–515, April 13, 2015 ª2015 Elsevier Inc.develop resistance to anti-leukemic therapies. Next-generation
sequencing has been used to characterize the AML genome
and to identify somatic disease alleles (Cancer Genome Atlas
Research Network, 2013; Welch et al., 2012). Analysis carriedoutcomes and define subtypes; however, in vivo models do
es. Here we show that TET2 and FLT3 mutations cooperate
leukemia stem cell population with a characteristic transcrip-
eting. The methylation changes exhibit cooperativity of dis-
at leukemic transformation by these epigenetic changes is
prove outcomes for AML patients.
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Figure 1. Development of Leukemic Disease in VTet2–/–Flt3ITD Mice
(A) Kaplan Meir survival curve of Tet2/ (n = 19), Flt3ITD (n = 23), Tet2+/;Flt3ITD (n = 26), and Tet2/;Flt3ITD (n = 28).
(B–D) Peripheral WBC count at 4 months (B), hematocrit at 4 months and at time of sacrifice (C), and peripheral blood Mac1 and cKit immunophenotype at
4 months (D), with the mean Mac1+ and cKit+ indicated (n = 5 to 12 per group).
(E) Peripheral blood morphology in Tet2/;Flt3ITD mice. Scale bar, 10 mm.
(F) Spleen weight at 4 months.
(G) Histology of bone marrow, lung, liver, and spleen of WT, Tet2/, Flt3ITD, and Tet2/;Flt3ITD mice. For bone marrow, lung, and liver, scale bars represent
100 mm; for spleen, the scale bar represents 200 mm. Green arrowheads indicate megakaryocytes.
(legend continued on next page)
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out in large AML cohorts has shown that these disease alleles
and their combination can be used to improved prognostic
schema (Hou et al., 2014; Patel et al., 2012). Recent studies
have also demonstrated the biologic and clinical relevance of
these alleles, including TET2, a gene targeted by mutations in
10%–20% of AML patients (Abdel-Wahab et al., 2009; Delhom-
meau et al., 2009; Langemeijer et al., 2009).
TET2mutations are associated with reduced response of AML
to chemotherapy and adverse overall survival (Metzeler et al.,
2011). In particular, TET2mutations are associated with adverse
outcome in the setting of concurrent FLT3ITD mutations (Hou
et al., 2014; Patel et al., 2012), suggesting thesemutations coop-
erate to induce a poor-prognosis subtype. Mutations in TET2
lead to loss of function and are often present as heterozygous
mutations, although a subset of patients has bi-allelic TET2
loss (Cancer Genome Atlas Research Network, 2013; Lange-
meijer et al., 2009). TET2 catalyzes the 5-hydroxylation of
methylcytosine to 5-hydroxymethylcytosine (5-hmC) leading to
DNA demethylation (Guo et al., 2011; Tahiliani et al., 2009).
TET2 mutant AML is characterized by reduced 5-hmC levels,
increased DNA methylation, and epigenetic silencing (Figueroa
et al., 2010; Ko et al., 2010; Rampal et al., 2014). In addition,
mutations in IDH1 and IDH2 inhibit TET2 function through pro-
duction of 2-hydroxyglutarate (Figueroa et al., 2010), and WT1
mutations lead to reduced TET2 function and reductions in 5-
hmC (Rampal et al., 2014). Collectively, the TET2 hydroxymethy-
lation pathway is altered by somatic mutations in 25%–35% of
AML and also in other hematologic and epithelial malignancies.
TET2 regulates hematopoietic stem cell (HSC) self-renewal.
In mouse models, conditional loss of Tet2 in the hematopoi-
etic compartment leads to expansion of stem cells (LSK,
linSca+cKit+) and increased repopulation ability in competitive
transplantation (Li et al., 2011; Moran-Crusio et al., 2011; Quiv-
oron et al., 2011). Tet2mutant mice develop a chronic myelopro-
liferative disease that does not consistently progress to AML. In
the human context, acquired mutations in TET2 and in genes en-
coding other epigenetic modifiers (e.g., DNMT3A, ASXL1) are
observed in subjects with clonal hematopoiesis without evi-
dence of an overt hematologic malignancy (Busque et al.,
2012; Xie et al., 2014). Analysis of AML and normal subjects
suggests mutations in TET2 and in epigenetic regulators can
represent early acquiredmutations in ‘‘pre-leukemic’’ stem cells,
which subsequently acquire further mutations leading to overt
transformation (Genovese et al., 2014; Jaiswal et al., 2014; Jan
et al., 2012). These data indicate that TET2 inactivation can
contribute to leukemia initiation but is not sufficient to induce
transformation to AML.
Flt3ITD mutations are found in nearly 30% of AML and
commonly co-occur with IDH1, IDH2, and TET2mutations (Patel
et al., 2012). The co-occurrence of FLT3ITD and TET2 mutations
implies these two alleles likely function together to induce trans-
formation. Previous studies have suggested that AML disease
alleles cooperate by altering distinct biological mechanisms,(H) Bone marrow CD71 and Ter119 immunophenotype, with mean of gates indic
(I) Serial plating in methylcellulose and colony counts (representative experiment
+p% 0.05, *p% 0.01, **p% 0.001, ***p% 0.0001. A log-rank test was used for su
Data shown in graphs indicate mean ± SEM. See also Figure S1.
504 Cancer Cell 27, 502–515, April 13, 2015 ª2015 Elsevier Inc.classified broadly as those acting on proliferation or on hemato-
poietic differentiation (Gilliland and Griffin, 2002). However, there
are additional possibilities, including the potential for specific
combinations of disease alleles to coordinately dysregulate
the expression of target loci. This can occur through gain-of-
function effects resulting in distinct epigenetic states with a
correspondingly altered transcriptional output. Here we investi-
gate loss of Tet2 together with Flt3ITD in AML development and
specifically how they interact to affect transcriptional and epige-
netic changes.
RESULTS
Tet2 Loss or Haploinsufficiency Combined with Flt3ITD
Results in AML In Vivo
To determine the functional significance of TET2 and FLT3ITD
mutations in AML, we generated mice harboring both mutations.
Conditional Vav-cre+Tet2fl/fl (VTet2/) mice were crossed to
the constitutive knockin Flt3ITD murine model (Lee et al., 2005)
to generate Vav-cre+Tet2fl/fl;Flt3ITD (VTet2/Flt3ITD) mice.
VTet2/Flt3ITD mice were viable at birth with no gross abnor-
malities; however, all mice expressing both disease alleles
developed a lethal hematopoietic disease with a median survival
of 36.7 weeks (Figure 1A). The survival of VTet2/Flt3ITD mice
was significantly reduced compared with mice expressing
either disease allele alone (VTet2/, Flt3ITD median survival
>80 weeks, p < 0.0001). After a median follow-up of more
than 1 year, no Flt3ITD mice developed leukemia, and less than
30%ofVTet2/mice died due to progressivemyeloproliferative
neoplasms (MPNs) and not AML. In addition, micewith Tet2 hap-
loinsufficiency and Flt3ITD developed a similar phenotype as
VTet2/Flt3ITD mice with median survival of 51 weeks (Fig-
ure 1A). We performed further analysis at 4 months when
VTet2/Flt3ITD mice had evidence of leukemia. VTet2/Flt3ITD
mice showed marked leukocytosis with a median white count of
35.8 k/ml (Figures 1B and S1A). At the time of sacrifice for
advanced disease, they developed progressive anemia (median
Hct 33.6%, p < 0.05), which was not observed in mice express-
ing either disease allele alone (median Hct 40%–51%) (Fig-
ure 1C). Analysis of the peripheral blood revealed increased
Mac1+ cells consistent with myeloid expansion, as well as an
expanded cKit+ population, and on peripheral smear leukocytes
exhibited blast-like morphology with enlarged, open nuclei (Fig-
ures 1D, 1E, and S1B).
VTet2/Flt3ITD mice were characterized by marked spleno-
megaly (mean 483 mg, p < 0.05; Tet2/ 145 mg, Flt3ITD
167 mg, wild-type [WT] 86 mg) and hepatomegaly (Figures 1F
and S1C). We observed infiltration of the bone marrow by a
monomorphic leukemic population with a decrease in the frac-
tion of mature hematopoietic (lineage+) cells and, by mor-
phology, the number of megakaryocytes (Figures 1G and S1D).
There was complete loss of splenic architecture, including
germinal centers along with splenic myeloid expansion (Figuresated (n = 4 to 6 per genotype).
of n = 3).
rvival statistics. Otherwise, an unpaired Student’s t test was used for p values.
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Figure 2. Stem-Progenitor Immunopheno-
type and Transplantability of VTet2–/–Flt3ITD
Mice
(A and B) Relative frequency of CMP, GMP, and
MEP progenitors in the linScacKit+ cell fraction
(A) and absolute GMP cell number (B) in bone
marrow.
(C and D) Relative frequency (C) and absolute cell
number (D) of LSK cells in lin bone marrow (n = 4
to 6).
(E–G) Analysis of transplanted mice. Peripheral
blood CD45.1 (host-derived marker) and CD45.2
(leukemia-derived marker) immunophenotype (E),
representative spleen size (millimeter scale) (F),
and representative peripheral bloodMac1 and cKit
immunophenotype (G) of CD45.1+ recipient mice
transplanted with CD45.2+ Tet2/;Flt3ITD LSK or
GMP cells (n = 4 per group).
(H) Flow plot of bone marrow LSK cells for MPP
(CD48+CD150) and LT-HSC (CD48CD150+)
frequency in WT and VTet2/Flt3ITD mice. Data
shown in gates represent mean ± SEM (n = 4).
(I) Re-plating colony counts of WT and Tet2/
cells sorted for LSK and GMP populations (repre-
sentative experiment from three replicates).
(J) TET2;FLT3ITD mutant human AML and normal
subject ST-HSC/MPP frequency (n = 9).
+p% 0.05, *p% 0.01, **p% 0.001, ***p% 0.0001.
An unpaired Student’s t test was used for p values.
Data shown in graphs indicate mean ± SEM. See
also Figure S2.1G and S1E). Similar findings were observed in the lung and liver,
with infiltration of leukemic cells in the alveolar and periportal re-
gions (Figure 1G). There was loss of CD71+Ter119+ erythroid
progenitors in the bone marrow consistent with impaired
erythroid differentiation (Figures 1H and S1F). As previously re-
ported for Flt3ITD induced disease, phospho-STAT5 levels are
elevated inVTet2/Flt3ITD cells comparedwithWT (Figure S1G).
To test whether VTet2/Flt3ITD bone marrow cells had a trans-
formed phenotype in vitro, we performed methylcellulose re-
plating. WT and Flt3ITD cells did not re-plate after three rounds,
but Tet2/ and Tet2/;Flt3ITD cells both continued to form
colonies for five rounds of plating, demonstrating Tet2 loss in-
creases in vitro self-renewal potential in the presence and
absence of Flt3ITD (Figure 1I). We also performed whole exome
sequencing on three VTet2/Flt3ITD leukemias but did not iden-
tify any recurrent mutations in leukemia disease alleles (Fig-
ure S1H). These data indicate that Tet2 loss combined with
Flt3ITD is sufficient to induce AML in vivo.Cancer Cell 27, 502–5Tet2 Loss and Flt3ITD Expression
Results in Altered Hematopoietic
Differentiation
Given the known role of Tet2 in regulating
stem cell differentiation, we analyzed
stem and progenitor compartments in
VTet2/Flt3ITD mice at 4 months.
VTet2/Flt3ITD mice had a significantly
higher percentage of granulocyte-macro-
phage progenitors (GMPs, lincKit+Sca-
1FcgR+CD34+) (mean, % of lin 80%,p < 0.0001) compared with WT (27%) or VTet2/ mice (32%),
while Flt3ITD mice also had an increased GMPs (63%) (Figures
2A and S2A). We observed a significant increase in the absolute
number of GMPs in VTet2/Flt3ITD mice compared with WT
or VTet2/ mice (Figure 2B). The increase in the frequency
of GMPs was associated with a decrease in the common
myeloid progenitor (CMP, lincKit+Sca-1FcgRCD34+) and
mega-erythroid progenitor (MEP, lincKit+Sca-1FcgRCD34)
populations. The frequency of LSKs was not increased in
VTet2/Flt3ITD mice within the lineage- fraction (Figure 2C);
however, we noted a significant expansion in the absolute num-
ber of LSK cells (mean, 4.13 105 LSKs/mouse versus 0.743 105
WT, 1.8 3 105 VTet2/, 2.1 3 105 Flt3ITD, p < 0.05) due to
marked expansion of the lineage population (Figures 2D and
S1D). These data demonstrate that the combination of Tet2
loss and Flt3ITD expression results in synergistic alterations in
stem and progenitor cells not seen with either mutant disease
allele alone, with expansion of the LSK and GMP populations.15, April 13, 2015 ª2015 Elsevier Inc. 505
LSK Cells and Not GMP Cells Are Leukemia Initiating
Cells in VTet2–/–Flt3ITD Mice
Transplantation studies of human leukemias demonstrated that
leukemia initiating capacity is highest in CD34+CD38 stem cells
(Bonnet and Dick, 1997). More recent studies have suggested
that leukemic stem cell (LSC) activity can also be detected in
committed myeloid progenitors (Kirstetter et al., 2008; Sarry
et al., 2011). In the murine context, transplantation studies using
MLL-fusion leukemia models have shown that GMPs can serve
as LSCs, with acquisition of self-renewal by committed progen-
itors (Heuser et al., 2011; Krivtsov et al., 2006). Since both the
LSK and GMP populations are expanded in VTet2/Flt3ITD
mice, we sought to determine if either population had leukemia
initiating capacity. LSK and GMP cells were sorted from bone
marrow of CD45.2 VTet2/Flt3ITD mice and transplanted into
CD45.1 recipient mice. Mice transplanted with LSK cells, but
not GMP cells, had progressive expansion of the CD45.2
donor population (Figures 2E and S2B). LSK transplanted mice
developed disease similar in phenotype to primary mice, with
splenomegaly, expansion of cKit+ blasts, and similar stem and
progenitor frequencies in the bone marrow re-establishing the
leukemic hierarchy (Figures 2F, 2G, and S2C). These data
demonstrate that the LSK, but not the GMP, population has
leukemic initiating potential.
The LSK population in VTet2/Flt3ITD mice displayed a
monomorphic immunophenotype consistent with selective ex-
pansion of the multipotent progenitor (MPP) population (LSK
CD48+CD150) (mean % of LSK 91% versus WT 59%, p <
0.001) (Figures 2H and S2D). By contrast, we observed near-
complete loss of the long-term (LT)-HSC (LSK CD48CD150+)
population (mean % of LSK 0.04% versus WT 8.2%, p < 0.01)
(Figures 2H and S2D–S2F). The frequencies of these populations
were also different from single mutant mice and maintained in
secondarily transplanted mice (Figures S2D and S2E). Second-
ary transplantation of sorted MPPs resulted in leukemic engraft-
ment similar to that observed with sorted LSKs (Figures S2G and
S2H). Thus, the MPP population, which is normally more limited
in self-renewal capacity, acquires self-renewal and LSC poten-
tial with Tet2 and Flt3 mutations.
The observation that LSKs, but not GMPs, could initiate leuke-
mia in secondary recipients suggested that Tet2 loss could in-
crease the self-renewal of LSKs but not of more committed
myeloid progenitors. Because the acquisition of serial re-plating
potential is due to Tet2 loss and not dependent on Flt3ITD, we
investigated the impact of Tet2 loss on LSK and GMP cells in
methylcellulose assays (Figure 2I). Tet2/ LSK cells had serial
re-plating potential, whereas Tet2/ GMP cells did not persist
beyond the third plating. This supports the observation that
LSK, and not GMP, derived cells are transformed by loss of
Tet2 and that the self-renewal program induced by Tet2 loss
is able to transform early stem-progenitors, but not more
committed populations. This is in contrast to MLL-fusion driven
leukemia, which is capable of transforming GMPs to LSCs
in vivo.
We next sought to determine stem and progenitor frequencies
in AML patients with concurrent TET2 and FLT3ITD mutations
(n = 9). TET2;FLT3ITD mutant AML patients were characterized
by a marked expansion in the proportion of short-term (ST)-
HSC/MPPs but variable numbers in the proportion of LT-HSCs506 Cancer Cell 27, 502–515, April 13, 2015 ª2015 Elsevier Inc.and GMPs (Figures 2J and S2I–S2P). We also observed a signif-
icant reduction in the proportion of CMPs (Figure S2K). Muta-
tional analysis of sorted populations (n = 6) showed that TET2
mutations were seen in LT-HSCs, ST-HSCs/MPPs, CMPs, and
GMPs, suggesting that TET2 mutations are acquired in HSCs
(Figure S2Q). FLT3ITD was also detectable in all these popula-
tions; however, they tended to be present at a lower allelic
burden than the TET2 mutation (Figure S2Q). This is in agree-
ment with the model in which TET2 mutations lead to pre-
leukemic clones that with additional mutations progress to
AML and expand specific subpopulations (Jan et al., 2012). In
addition, these data support the notion that the expansion of
ST-HSC/MPPs in TET2;FLT3ITD mutant AML is not due to selec-
tive acquisition of thesemutations in this compartment but rather
due to clonal expansion of specific populations in TET2;FLT3ITD
mutant AML.
VTet2–/–Flt3ITD AML Is Refractory to Chemotherapy
In order to assess the impact of anti-leukemic therapies on
VTet2/Flt3ITD AML cells compared with normal hematopoi-
etic cells, we tested the therapeutic efficacy of doxorubicin
and cytarabine in CD45.1 mice transplanted with CD45.2
VTet2/Flt3ITD AML cells (n = 5 per group). Mice were treated
with vehicle or doxorubicin and cytarabine for 5 to 7 days fol-
lowed by assessment of disease burden (Figure 3A). Induction
chemotherapy with doxorubicin and cytarabine induced pancy-
topenia with a similar severity and kinetics as observed with
induction therapy in human AML (Figure S3A). This therapy
was effective in reducing and in some cases eliminating the
leukemic clone in AML1-ETO driven leukemias, consistent with
previous reports (Figures S3B–S3G) (Zuber et al., 2009). In
VTet2/Flt3ITD disease, chemotherapy resulted in a transient
decrease in the proportion of AML (CD45.2) cells; however, by
4 weeks all mice again developed marked leukocytosis (Fig-
ure 3B). Furthermore, with recovery from pancytopenia, the
AML clone had expanded and there was no reduction in spleno-
megaly (Figures 3C and S3H). Thus, VTet2/Flt3ITD AML is che-
moresistant relative to other sensitive AML genotypes.
VTet2–/–Flt3ITD LSCs Are Refractory to FLT3-Targeted
Therapy
FLT3 inhibitors have clinical activity in FLT3ITD mutant AML but
do not achieve sustained remission (Kayser and Levis, 2014;
Smith et al., 2012). To understand the nature of this response,
we assessed leukemic burden in mice transplanted with
VTet2/Flt3ITD cells following treatment with the FLT3 inhibitor
AC220 (n = 5) (Figure 3A). AC220 treatment (10 mg/kg) for
4 weeks led to a reduction in leukocyte count and a modest
reduction in spleen weight and leukemic burden (Figures 3B,
3C, and S3H). However, we observed persistent cKit+ blast
cells in the blood of mice treated with AC220 therapy (Figure 3D).
This is in contrast to reported FLT3 inhibition in Flt3ITD mice
where aberrant differentiation is effectively reversed (Chu et al.,
2012).
We next assessed differential effects of FLT3 inhibition
on LSCs and on bulk leukemia cells. We treated primary
VTet2/Flt3ITD mice with vehicle or AC220 (10 mg/kg) (n = 3
per group). Mice treated with AC220 for 3 weeks had smaller
spleens and reduced white blood cell (WBC) counts consistent
E F 
H
I 
G
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D 
Figure 3. Response of VTet2–/–Flt3ITD Leu-
kemia to AC220 and Chemotherapy
(A) Treatment scheme with secondary trans-
planted CD45.2+ Tet2/;Flt3ITD bone marrow into
CD45.1+ mice (n = 5 per group).
(B–D) Peripheral blood WBC count after treatment
for 4 weeks (B), CD45.1 (host-derived marker)
and CD45.2 (leukemia-derived marker) immuno-
phenotype at 2 weeks and 4 weeks (C), and Mac1
and cKit immunophenotype at 4 weeks (D) of
vehicle, chemotherapy treated, and AC220 treated
mice.
(E and F) Spleen size (E) and peripheral bloodWBC
count (F) of VTet2/Flt3ITD mice treated with
vehicle or AC220 for 4 weeks (n = 3 per group).
(G–I) Bone marrowmyeloid progenitor analysis (G),
LSK percentage and absolute number (H), and
SLAM LSK immunophenotype analysis; gates are
indicated for MPPs (CD48+CD150) and LT-HSC
(CD48CD150+) fractions (I) following vehicle,
chemotherapy, or AC220 treatment.
+p% 0.05, *p% 0.01, **p% 0.001, ***p% 0.0001.
An unpaired Student’s t test was used for p values.
Data in graphs and flow plot numbers indicate
mean ± SEM. See also Figure S3.with an inhibitory effect on the bulk leukemic population (Figures
3E and 3F). AC220 therapy increased the proportion ofMEP cells
while decreasing that of GMPs, suggesting that myeloid progen-
itors remain sensitive to FLT3 inhibition (Figure 3G). By contrast,
FLT3 inhibition did not reduce the absolute number of LSK cells,
indicative of a lack of efficacy on AML LSCs (Figure 3H). There
was a trend toward increased LSK frequency due to a relative
decrease in the other cell populations (Figure 3H). In addition,
AC220 therapy did not inhibit LSC function, as recipients trans-
planted with cells from AC220 treated mice developed disease
with similar kinetics as those from vehicle treated mice (Figures
S3I and S3J). Furthermore, treatment with induction chemo-
therapy or with AC220 did not alter the immunophenotype of
the LSK compartment with continued expansion of the MPPs
and reduction of the LT-HSCs (Figure 3I). These data indicateCancer Cell 27, 502–that VTet2/Flt3ITD LSCs are refractory
to FLT3 targeted therapy and to cytotoxic
chemotherapy and suggest that there
may be specific gain-of-function gene
regulatory effects by combinatorial ac-
tions of Tet2/ and Flt3ITD in LSCs that
confer this phenotype.
Transcriptional and Methylation
Profiling Reveal that VTet2–/–Flt3ITD
LSC Have a Unique Signature
In order to understand the basis for
the leukemic phenotype, we performed
RNA sequencing (RNA-seq) on LSK and
GMP cells from WT and VTet2/Flt3ITD
mice. Unsupervised hierarchical clus-
tering showed that LSK cells from WT
and mutant mice were more similar to
each other than to GMPs of the samegenotype, again supporting the observation that mutant GMPs
had not gained a stem-like signature (Figures 4A and S4A).
ComparedwithWT LSK cells, Tet2/;Flt3ITD LSKs had a distinct
gene expression signature, with dysregulated expression of
known self-renewal and differentiation genes including Id1,
Gata1, Gata2, Mpl, and Socs2 (Figures 4B and S4B; Tables S1
and S2). This signature also was distinct from Tet2/ or Flt3ITD
LSKs (Figure S4C). Gene set enrichment analysis (GSEA) anal-
ysis showed that VTet2/Flt3ITD LSK cells were characterized
by enrichment of an embryonic stem cell signature and reduced
expression of a GATA target signature (Figure 4C) (Liberzon
et al., 2011; Wong et al., 2008).
Previous studies have shown that TET2 mutant AMLs are
characterized by site-specific changes in DNAmethylation (Aka-
lin et al., 2012a; Figueroa et al., 2010). We therefore performed515, April 13, 2015 ª2015 Elsevier Inc. 507
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Figure 4. RNA-Seq and Methylation Analysis of VTet2–/–Flt3ITD Mice
(A and B) Heatmap from RNA sequencing expression analysis of WT and Tet2/;Flt3ITD bone marrow LSK and GMP cells (A) and LSK cells for genes ranked by
fold change > 3.5 and FDR < 105 (B). Z score scale.
(C) GSEA enrichment plot of Tet2/;Flt3ITD LSK RNA expression correlated with the embryonic stem cell signature and negatively correlated with GATA1
signature.
(D) Dendrogram clustering based on eRRBS methylation profiles from WT and Tet2/;Flt3ITD (T2F3) LSK cells.
(E) Gene localization of hypermethylated and hypomethylated differentially methylated regions (DMRs) in Tet2/;Flt3ITD LSK cells, percentages.
(F) GSEA enrichment plot correlating hypermethylation promoter genes with genes with downregulated expression trend in Tet2/;Flt3ITD LSK cells.
See also Figure S4 and Tables S1, S2, and S3.
508 Cancer Cell 27, 502–515, April 13, 2015 ª2015 Elsevier Inc.
methylation profiling of VTet2/Flt3ITD, single mutant, and WT
LSK cells using enhanced reduced representation bisulfite
sequencing (eRRBS) to evaluate CpG regions (Table S3). Hierar-
chical clustering by differentially methylated cytosines (DMCs)
demonstrated clear separation of leukemic VTet2/Flt3ITD
LSKs from WT LSKs (Figure 4D). We next analyzed the grouping
of DMCs into differentially methylated regions (DMRs). The ma-
jority of DMRs in VTet2/Flt3ITD LSKs were located in gene reg-
ulatory elements, with a distribution that was distinct from those
of single mutant LSKs (Figures 4E and S4D). CpG islands and
particularly CpG shores have been described to be critical regu-
latory regions for hematopoiesis (Ji et al., 2010). Hypermethy-
lated DMRs in VTet2/Flt3ITD LSKs were more frequently
located in promoter regions and CpG shores compared with
other DMRs groups, suggesting gene regulatory function (Fig-
ures 4E and S4D). Principle component analysis of the DMRs
showed that VTet2/Flt3ITD LSK cells form a separate group
from single mutants LSKs, suggesting a functional correlation
between genotype and variation in methylation (Figure S4E).
GSEA analysis demonstrated hypermethylated promoter re-
gions were enriched for genes with a trend in decreased ex-
pression based on RNA-seq data, consistent with epigenetic
silencing through hypermethylation (Figure 4F). We identified
58 genes with altered differential expression and promoter
or gene body hypermethylation in VTet2/Flt3ITD LSK cells
compared with WT (Table S4). These include Gata2, Hox genes,
Smarca2, and Dusp4 genes with known roles in hematopoiesis
and differentiation. These data indicate that key regulatory genes
are epigenetically modified and altered in expression as a result
of Tet2 and Flt3 mutation.
Concurrent Tet2 and Flt3ITD Mutations Result in
Synergistic Effects on DNA Methylation and Gene
Expression
With the observation that concurrent mutations in Tet2 and
Flt3ITD cooperate to induce AML, we hypothesized that the com-
bination of these disease alleles would result in a synergistic ef-
fect on the epigenetic state and on gene expression. Compared
with Tet2/ or Flt3ITD LSKs, Tet2/;Flt3ITD LSKs had a dramatic
increase in the number of DMRs; we observed 1,704 DMRs in
Tet2/;Flt3ITD, 174 in Tet2/, and 200 in Flt3ITD LSKs (Fig-
ure 5A). Tet2/ LSKs displayed proportionally greater hyperme-
thylation versus WT LSKs, whereas Flt3ITD LSKs had predomi-
nant hypomethylation. The combination of VTet2/Flt3ITD had
greater DNA hypermethylation, similar in direction (but not in
extent) to that observed in Tet2/ LSK cells (Figure 5B). We
observed that Tet2/;Flt3ITD mutation resulted in DMCs at loci
distinct from those affected in Flt3ITD or Tet2/ LSKs (Fig-
ure S5A); similarly, the number of hypermethylated DMCs per
genetic loci was also significantly different (Figure 5C). The ma-
jority of genes with DMRs in Tet2/;Flt3ITD LSKs were unique
from the smaller set of those observed in Tet2/ or Flt3ITD
LSKs (Figure 5D). Therefore, the impact of Tet2/;Flt3ITD muta-
tions on DNA methylation was much greater than would be
expected from the additive effects of single Tet2 and Flt3ITD mu-
tations, implying changes in methylation are a consequence of
the cooperative effects of Tet2 loss and Flt3ITD.
In order to identify target loci with potential functional rele-
vance, we focused on genes with altered expression andmethylation in the setting of concurrent Tet2 and Flt3ITD muta-
tions. We identified the set of differentially expressed genes in
VTet2/Flt3ITD and then targeted loci where the combination
of Tet2 and Flt3ITD mutations had a cooperative gain-of-function
effect onmethylation using logistic regression and pairwise com-
parisons (VTet2/Flt3ITD versus single mutants). We identified
115 genes that exhibited cooperative effects onDNAmethylation
(R3 DMCs) and altered expression (Tables S5 and S6; Fig-
ure S5B). For the majority of the loci that demonstrated coopera-
tivity, we observed DNA hypermethylation and transcriptional
silencing (Table 1 and Figure 5E). The pattern of expression of
the subset of these genes with the greatest methylation differ-
ences (R6 DMRs, see Table 1) demonstrated a distinct expres-
sion profile in Tet2/;Flt3ITD LSKs compared with WT or single
mutant LSKs (Figure 5F). Notably, of the 27 genes with promoter
DMRs and differential expression, 19 were differentially methyl-
ated in TET2 mutant AML patients (Table S6) (Akalin et al.,
2012a). We next analyzed methylation in ST-HSC cells from
TET2;FLTITD AML patients (n = 2) by performing eRRBS and
compared DNA methylation to normal CD34+ cells (n = 13). We
identified 83 genes that had at least 5 promoter DMCs in murine
Tet2/;Flt3ITD LSKs comparedwithWT LSKs and also had a hu-
man ortholog; 53 of these 83 genes had at least one DMC in
TET2;FLT3ITD AML ST-HSCs (p = 4.8 3 108), and 33 of 83 had
5 or more DMCs (p = 2.8 3 106) (Table S7).
Epigenetic Silencing of Gata2 Contributes to Impaired
Differentiation in VTet2–/–Flt3ITD LSC
The Gata2 locus in VTet2/Flt3ITD LSKs was characterized by
marked hypermethylation at the promoter, introns, and a key
enhancer region compared with WT and single mutant LSKs
(Figure 5G) (Snow et al., 2010). Expression analysis of Gata2 in
sorted LSK cells demonstrates that concomitant Tet2 and Flt3ITD
mutations led to significant decreased levels of RNA expression
(Figure 5H). TheGATA2 locus was also densely hypermethylated
in human TET2;FLT3ITD AML cells, with 45 DMCs in the GATA2
locus in leukemic ST-HSCs compared with normal CD34+ cells
(Figure 5G).
To determine the impact of Flt3ITD inhibition on Gata2 expres-
sion, we assessed the expression level of Gata2 in LSK cells
sorted from vehicle or AC220 treated VTet2/Flt3ITD mice.
Gata2 expression modestly increased with AC220 therapy, but
did not return to WT levels (Figure S5C). This suggests that the
cooperative activities of bothmutations are required to epigenet-
ically silence the Gata2 locus and that targeting one mutant
allele alone is not sufficient to reverse the coordinate effects
on the transcriptome. We then analyzed the impact of FLT3
inhibition with AC220 on locus-specific DNA methylation in
VTet2/Flt3ITD LSKs. Despite evidence of effect on bulk leuke-
mia cells with reductions in WBC count and spleen size, AC220
treatment did not substantively alter the overall LSK methylation
status as individual DMRs remained highly correlated between
naive and treated LSKs (Figures 5I and S5D–S5F). Clustering
by methylation status showed that AC220-treated LSKs were
indistinguishable from vehicle treated or naive VTet2/Flt3ITD
LSKs and were distinct from Tet2/ LSKs (Figures S5G and
S5H). Consistent with the transcriptional data, the methylation
status of Gata2 locus was largely unaffected by AC220 therapy
(Figure 5G).Cancer Cell 27, 502–515, April 13, 2015 ª2015 Elsevier Inc. 509
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Figure 5. Flt3ITD Mutation and Tet2 Loss Synergistically Regulate Gene Expression
(A and B) Number of differentially methylated regions (DMRs) (A) and chromosomal hypermethylation and hypomethylation proportions (B) in Tet2/, Flt3ITD, and
Tet2/;Flt3ITD LSKs.
(C) Heat map of number of hypermethylated differentially methylated cytosines (DMCs) in 424 genes in Tet2/;Flt3ITD LSKs compared with the number of DMCs
in Tet2/ and Flt3ITD LSKs.
(D) Venn diagram of genes associated with DMRs for each genotype.
(legend continued on next page)
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We next sought to assess whether restoring Gata2 expres-
sion would alter differentiation and inhibit leukemogenesis in
VTet2/Flt3ITD cells. We expressed Gata2 and MIGR1 control
using a GFP-expressing vector in bone marrow cells from
VTet2/Flt3ITD mice. When plated in methylcellulose, control
VTet2/Flt3ITD colony cells showed reduced CD71 positivity,
consistent with impaired erythroid differentiation (Figures 5J
and S5I). By contrast, VTet2/Flt3ITD cells re-expressing
Gata2 had increased CD71 expression (Figures 5J and S5I).
These data imply Tet2/;Flt3ITD bonemarrow cells are not irrev-
ocably blocked but are capable of differentiating when Gata2 is
re-expressed. We next assess the impact of re-expressing
Gata2 in vivo by transplanting Tet2/;Flt3ITD bone marrow
cells expressing control GFP or Gata2 into recipient mice.
Cells expressing Gata2 engrafted in vivo; however, we observed
a marked reduction in the proportion of Gata2 positive
VTet2/Flt3ITD myeloid leukemia cells compared with Gata2
positive erythroid cells, consistent with in vivo erythroid differen-
tiation of AML cells (Figure 5K). Furthermore, Gata2 expression,
but not expression of vector control, resulted in a progressive
reduction in the proportion of cKit+ Tet2/;Flt3ITD leukemic
cells, correlating with disappearance of the AML clone (Figures
5K and S5J). Notably, mice expressing vector alone succumbed
to leukemia, whereas no mice expressing Gata2 developed
lethal AML (Figure 5L). These data demonstrate that Gata2 re-
expression can restore differentiation and attenuates leukemo-
genesis in vivo.
DISCUSSION
Mutations that dysregulate the DNA hydroxy-methylcytosine
pathway are among the most common disease alleles in human
cancers and include mutations in TET2, as well as mutations in
IDH1, IDH2, andWT1 that can lead to inhibition of TET2 function.
As such, there is a need to delineate how these mutations
contribute to malignant transformation, the epigenetic state,
and alterations in transcriptional output. Here we show that
Tet2 loss combined with Flt3ITD causes leukemia in vivo and
that these two disease alleles cooperate to induce synergistic
and gain-of-function effects on DNA methylation and gene
expression.
Previous studies using Tet2 conditional knockout mice impli-
cate a role for TET2 in regulating stem cell self-renewal. These
data with studies demonstrating TET2 mutations establishing
clonal hematopoiesis and a pre-leukemic state in the human
context suggest that TET2mutations enhance stem cell function(E) Bar graph of paired DMC number (in red) and expression change (in blue) for
(F) Heat map of RNA expression based on genes in Table 1 (R6 DMCs and altered
(G) Gata2 locus methylation for LSK cells, LSK cells following treatment, and
methylation). Also, location of DMRs and DMCs as determined through eRRBS a
(H) Gata2 relative RNA expression in LSK cells.
(I) Scatter plot of corresponding DMRs between Tet2/;Flt3ITD LSKs and Tet2
samples by red lines (PearsonCorr = 0.948).
(J) CD71 and Mac1 immunophenotype of methylcellulose colonies from Tet2/
shown.
(K and L) Peripheral blood GFP% of red blood cells (RBC), Mac1+ cells, and c
transplanted with MIGR1 (n = 7) and Gata2 (n = 5) transduced Tet2/;Flt3ITD bo
*p% 0.01, ***p < 0.0001, using unpaired Student’s t test. Data in graphs indicate m
and Tables S4, S5, S6, and S7.and initiate the process of malignant transformation. Similarly,
studies have shown that a broader spectrum of leukemia disease
alleles, including those in DNMT3A and in ASXL1, can promote
clonal hematopoiesis without inducing AML. TET2 loss has a
second, critical function in leukemic transformation, as it can
cooperate with other AML disease alleles to coordinately dysre-
gulate DNA methylation and alter expression at target loci. This
effectively maintains the block in hematopoietic differentiation
and increases self-renewal of AML LSCs after malignant trans-
formation. These data demonstrate a role for TET2 mutation in
leukemic maintenance distinct from inducing clonal expansion
and suggest that mutations in epigenetic modifiers can act at
multiple steps during leukemogenesis.
We identify the LSC population in our model of TET2;FLT3ITD
mutant AML in the MPP compartment, a population that has
also been found to be expanded in human AML samples and
to be capable of leukemia propagation in xenotransplant
studies (Goardon et al., 2011). Although the combination of
Tet2 and Flt3 mutations in our mouse model was sufficient to
promote leukemogenesis, additional mutations and chromo-
somal alterations are sometimes seen in TET2;FLT3ITD mutant
human AML (Cancer Genome Atlas Research Network, 2013),
suggesting additional events may be required to transform hu-
man LSCs. However, we find significant overlap between the
set of differentially methylated genes in our model and in human
AML stem-progenitor cells, suggesting that this combination of
mutations leads to similar effects on DNA methylation.
Although theTET family of enzymes is critical in regulating DNA
methylation, the target genes and pathways affected have not
been well characterized in AML or other human cancers. We
demonstrate that Tet2;Flt3ITD mutant AML has a unique epige-
netic and transcriptional signature and that LSCs in Tet2;Flt3ITD
mutant AML are characterized by increased expression of a
stem cell gene expression program and by reduced expression
of Gata2 and of a GATA-associated gene expression signature.
These data underscore recent studies showing that Idh2;Flt3ITD
mutant AML is characterized by a reduced GATA gene expres-
sion signature (Kats et al., 2014) and that IDH1 and IDH2mutant
AML samples are characterized by differential methylation of
GATA target genes (Figueroa et al., 2010). Consistent with these
data, we found that GATA2 is hypermethylated in TET2;Flt3ITD
human AML stem-progenitor cells. Furthermore, AML profiling
has identified somatic GATA2 mutations and dysregulated
GATA2 expression (Celton et al., 2014; Cancer Genome Atlas
Research Network, 2013; Gro¨schel et al., 2014). Our data are
also consistent with reports in which human HSC differentiationgenes with promoter and intron DMCs and differential RNA expression.
expression in Tet2/;Flt3ITD LSKs) for LSKs of each genotype. Z score scale.
human ST-HSC leukemia and CD34+ cell populations (scaled to average
nalysis.
/;Flt3ITD AC220 treated LSKs. Fitted line in blue; ±20% variation between
;Flt3ITD cells expressing MIGR1 control or Gata2, with mean gate frequency
Kit+ cells at 3 weeks and 9 weeks (K) and leukemia free survival (L) of mice
ne marrow.
ean ± SEM. A log-rank test was used for survival statistics. See also Figure S5
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Table 1. Genes Demonstrating Synergistic Interaction of Tet2–/–
and Flt3ITD on Methylation in Tet2–/–;Flt3ITD LSK Cells, with
Altered Gene Expression
Gene Symbol
Hyper DMC Numbera Hypo DMC Numbera
log2FCT2F3 Tet2/ Flt3ITD T2F3 Tet2/ Flt3ITD
MN1 91 3 0 0 0 0 2.24
HOXA3 51 0 1 0 3 1 2.19
GATA2 39 0 12 0 2 1 2.99
ZFPM1 27 0 2 0 0 0 2.85
GM53 23 0 0 0 0 1 6.92
LTBP3 22 0 0 0 0 0 1.68
GSE1 23 0 4 2 2 0 1.42
FAM110A 17 0 0 0 0 0 1.26
RAPGEF3 15 0 4 0 0 0 2.88
TRIM47 14 0 3 0 1 0 3.54
RUNX3 14 0 0 1 0 1 1.05
GDF10 12 0 1 0 0 0 9.23
ADCY9 12 0 0 0 0 0 1.64
HOXB3 12 0 0 0 0 0 2.11
RPS4Y2 12 0 0 0 0 0 3.48
TSHZ2 14 0 3 3 0 3 6.64
FLT1 12 0 1 1 0 0 2.31
SCUBE3 11 0 0 0 1 0 1.65
CUEDC1 10 0 1 0 3 2 1.86
2700081O15RIK 10 0 0 0 0 0 2.10
STAP2 15 0 1 7 0 0 6.04
KCTD1 8 0 1 0 2 1 1.05
ZFHX3 8 0 3 0 0 0 1.21
NRG1 8 0 0 0 0 0 5.67
PCDHGB6 8 0 0 0 0 0 2.46
HLF 7 10 2 0 0 0 2.74
AGAP1 8 0 2 1 0 0 1.30
ARAP3 7 0 2 0 0 0 1.56
TCF7 7 0 0 0 0 2 1.78
C230081A13RIK 7 0 0 0 0 0 1.02
GDF3 7 0 0 0 0 0 4.66
RAI1 7 0 0 0 0 0 1.12
MDGA1 7 0 1 1 0 0 3.13
TMEM215 6 0 0 0 0 1 2.35
CORO7 6 0 0 0 0 0 0.93
ARID1B 6 0 0 1 0 0 1.03
TMEM51 6 0 0 2 0 0 3.61
RASSF4 0 0 0 6 0 0 2.31
REPS1 0 0 0 7 0 4 1.39
CISH 0 0 0 18 1 4 2.81
LSK, (linSca+cKit+) cells; Hyper, Hypermethylation; Hypo, Hypomethy-
lation; T2F3, Tet2/;Flt3ITD synergy component; log2FC, log 2 fold
change of gene expression in Tet2/;Flt3ITD LSKs compared with wild-
type LSKs.
aDMC contribution of the allele or allele combination to overall gene
methylation (gene body and 5 kb 50 region) calculated by logistic regres-
sion analysis, filtered forR6 DMC.
512 Cancer Cell 27, 502–515, April 13, 2015 ª2015 Elsevier Inc.to the erythroid lineage acquires 5-hmC at binding sites enriched
forGATA1andGATA2motifs anddependsonTET2 (Madzoet al.,
2014; Pronier et al., 2011). Undoubtedly, there are additional
genes that are dysregulated in TET2 and IDH mutant AMLs that
cancontribute to leukemic transformation; theymayalso varyde-
pending on the specific cooperating mutation.
Although loss of Tet2 alone leads to alterations in DNAmethyl-
ation andgene expression,we found that the combination ofTet2
loss with expression of FLT3ITD results in synergistic and gain-of-
function effects on the epigenetic state and on transcription. Pre-
vious studies in AML and in other malignancies have suggested
that different somatic mutations combine to induce transforma-
tion by endowing a cancer cell with discrete, necessary biologic
features; ourdata suggest that theremaybespecific target genes
that serve as convergent nodes for cooperative transformation
requiring combinations of mutations. We observe that inhibition
of FLT3 signaling alone is not sufficient to reverse themethylation
changes in Tet2;Flt3ITD mutant LSCs. One could speculate that
since TET2 is required for demethylation, once certain CpGs
become methylated in the combined TET2;FLT3ITD mutant
setting, even if FLT3 signaling is blocked, without sufficient
TET2 activity, the methylation status cannot be reset. This pro-
vides another possiblemechanismof resistance to FLT3directed
therapy—specifically the persistent altered epigenetic state of
LSCs that is not reversed by FLT3 inhibitor monotherapy.
The observation that ectopic expression ofGata2 can promote
differentiation ofVTet2/Flt3ITDmutant AML cells demonstrates
that Tet2;Flt3ITD mutant LSCs have an epigenetic signature that
does not irrevocably alter their differentiation and self-renewal
potential. These data suggest that therapies that can reverse
this signature will offer significant therapeutic efficacy in AML pa-
tients with mutations in TET2, IDH1, or IDH2. This may include
combination therapies that incorporate epigenetic modulators
such as hypomethylating agents and bromodomain inhibitors,
or targeted therapies such as the mutant IDH1 and IDH2 inhibi-
tors (Rohle et al., 2013; Wang et al., 2013). Clinical studies indi-
cate increased sensitivity to hypomethylating agents in TET2
mutant patients (Bejar et al., 2014; Traina et al., 2014), which
may reflect an ability to reverse the effects of TET2 mutations
on DNA methylation by these agents. Studies in preclinical
models and in the clinical setting will determine if these or other
epigenetic therapies can be used to potently and specifically
reprogram leukemia stem cells to induce differentiation, and
to determine how best to incorporate epigenetically targeted
agents into multimodality therapies.EXPERIMENTAL PROCEDURES
Transgenic Animals
The conditional Vav-cre+ Tet2fl/fl mice were previously described (Moran-
Crusio et al., 2011), and Flt3ITD mice were kindly provided by Gary Gilliland
(University of Pennsylvania). Pathology was obtained after fixation in 4% para-
formaldehyde (PFA) and slides stained with H&E. All animal procedures were
conducted in accordance with the Guidelines for the Care and Use of Labora-
tory Animals and were approved by the Institutional Animal Care and Use
Committees at Memorial Sloan Kettering Cancer Center.In Vitro Colony Forming Assays
Bone marrow cells (whole or sorted populations) were seeded into cyto-
kine supplemented methylcellulose medium (Methocult, M3434, STEMCELL
Technologies). Colonies propagated in culture were scored at day 7 to 10.
Cells were resuspended and re-plated at 15,000 cells per well.
Bone Marrow Transplantation
Dissected femurs and tibias were isolated. Bone marrow was flushed with a
syringe into RPMI 10% fetal calf serum (FCS) media. Spleens were isolated
and single cell suspensions made by mechanical disruption using glass slides.
Cells were passed through a 70 mmstrainer. Red blood cells (RBCs) were lysed
in ammonium chloride-potassium bicarbonate lysis buffer for 10 min on ice.
Finally, 1 3 106 total cells were transplanted via tail vein injection into lethally
irradiated (23 550 Rad) C57BL/6 or CD45.1 host mice. For sorted cell popula-
tions, 13 105 (LSK), 33 105 (GMP), and 43 105 (GFP+) cells were transplanted
in combination with support marrow.
In Vivo Treatment Studies
Mice were treated daily using oral gavage with AC220 at 10mg/kg, suspended
in 5% 2-hydroxypropyl-b-cyclodextrin. Mice were treated with combination
chemotherapy using protocol previously described (Zuber et al., 2009).
Briefly, mice were treated for 5 to 7 days daily with intraperitoneal injections
of 100 mg/kg cytarabine and for 3 days with 3 mg/kg doxorubicin.
RNA Sequencing and Analysis
Cell populations were sorted using BD FACSAria and RNA isolated using Tri-
zolLS. RNA was prepared using RiboMinus from LifeTechnologies. The library
was sequenced using the Ion Proton System from LifeTechnologies. Aligned
RNA was analyzed for fold change. See Supplemental Information for details
of analysis.
eRRBS and Differential Methylation Analysis
eRRBS was performed using a protocol previously described (Akalin et al.,
2012a). Briefly, genomic DNA were digested with MspI. DNA fragments
were end-repaired, adenylated, and ligated with Illumina kits. Library frag-
ments of 150–250 bp and 250–400 bp were isolated. Bisulfite treatment was
performed using the EZ DNA Methylation Kit (Zymo Research). Libraries
were amplified and sequenced on an Illumina HiSeq. Differential methylation
analysis was performed on the resulting eRRBS data using methylKit (Akalin
et al., 2012b) for finding single nucleotide differences (q value < 0.01 and
methylation percentage difference of at least 25%) and empirically based
differentially methylated regions (eDMRs) (Li et al., 2013) for finding DMRs.
See Supplemental Information for details of analysis.
Retroviral Transduction
The MSCV Gata2 construct was provided by Dr. John Crispino (Northwestern).
Virus was produced by transfecting 293T cells with MSCV and EcoPack plas-
mids.Bonemarrowwas harvested 6 days after 5FU (150mg/kg) treatment. After
red cell lysis, the cells were cultured inmedia containing RPMI/10% fetal bovine
serum (FBS) and IL-3 (7 ng/ml), IL-6 (10 ng/ml), and stem cell factor (10 ng/ml).
Cells were infected twice in the presence of polybrene and HEPES buffer.
Flow Cytometry and Fluorescence-Activated Cell Sorting
Antibody staining and fluorescence-activated cell sorting (FACS) analysis
were performed as previously described (Moran-Crusio et al., 2011). Intra-
cytoplasmic staining was performed with the Cytofix Cytoperm kit from BD
Biosciences. Stem cell enrichment was performed using the Progenitor Cell
Enrichment Kit (STEMCELL Technologies). Isolation of human stem and pro-
genitor populations from mononuclear cells was performed as previously
described (Barreyro et al., 2012). See Supplemental Information for antibodies.
Patient Samples
AML samples were obtained at diagnosis from patients enrolled in the Eastern
Cooperative Oncology Group’s (ECOG) 1900 clinical trial. All patients provided
informed consent. Approval was obtained from the Institutional Review Board
at Memorial Sloan-Kettering Cancer Center.
ACCESSION NUMBERS
RNA sequencing data have been deposited in GEO under accession number
GSE57244 and the eRRBS data under GSE57114.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.03.009.
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